Application Value of Combined Detection of Serum IGF-I and IGFBP-3 in the Diagnosis of Bladder Cancer

Abstract

Objective. To investigate the application value of the combined detection of serum IGF-I and IGFBP-3 in the diagnosis of bladder cancer (BC). Methods.Sixty BC patients in our hospital (January 2019-January 2020) were chosen as group A, while sixty healthy people during the same period were chosen as group B. The serum IGF- I and IGFBP-3 levels of the subjects were detected to explore the relationship between the two levels (serum IGF- I and IGFBP-3) and BC.Results.Compared with group B, the two levelsof group A were lower while IGF-I/IGFBP-3 was higher. Compared with low-grade BC group, non-muscle invasive BC (NMIBC) group and non-lymph node metastasis group, the two levels were lower in high-grade BC group, muscle-invasive BC (MIBC) group and lymph node metastasis group (P<0.05). No notable difference in IGF-I/IGFBP-3 was found among patients with high-grade or low-grade BC, with or without lymph node metastasis, andwith or without muscular invasion (P>0.05).Conclusion. The serum IGF-I and IGFBP-3 levels of BC patients are obviously different compared with healthy people, and vary in patients with different types of BC, indicating the two factors can be applied in clinical diagnosis of BC.